Page last updated: 2024-09-05

n-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid and lysine

n-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid has been researched along with lysine in 1 studies

Compound Research Comparison

Studies
(n-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid)
Trials
(n-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid)
Recent Studies (post-2010)
(n-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid)
Studies
(lysine)
Trials
(lysine)
Recent Studies (post-2010) (lysine)
400737,44962211,213

Protein Interaction Comparison

ProteinTaxonomyn-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid (IC50)lysine (IC50)
Cationic amino acid transporter 3Homo sapiens (human)158

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Baidoo, K; Boswell, CA; Brechbiel, MW; Choyke, PL; Gunn, AJ; Milenic, DE; Xu, H1

Other Studies

1 other study(ies) available for n-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid and lysine

ArticleYear
Design, synthesis, and characterization of a dual modality positron emission tomography and fluorescence imaging agent for monoclonal antibody tumor-targeted imaging.
    Journal of medicinal chemistry, 2007, Sep-20, Volume: 50, Issue:19

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Binding, Competitive; Carbocyanines; Cell Line, Tumor; Chelating Agents; Drug Design; Flow Cytometry; Fluorescent Dyes; Humans; Immunoconjugates; Indium Radioisotopes; Isothiocyanates; Lysine; Pentetic Acid; Positron-Emission Tomography; Radioimmunoassay; Radiopharmaceuticals; Trastuzumab; Yttrium Radioisotopes

2007